We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J Stance on Biosimilar Naming Shows Growing Industry Rift on Issue
J&J Stance on Biosimilar Naming Shows Growing Industry Rift on Issue
Highlighting a growing dispute in the pharmaceutical industry, Johnson & Johnson is arguing that biosimilars should have international non-proprietary names (INN) that are similar to, but distinguishable from, reference products.